RESEARCH ARTICLE

Isoform Switch of Pyruvate Kinase M1 Indeed Occurs but Not to Pyruvate Kinase M2 in Human Tumorigenesis

Cheng Zhan1, Li Yan2, Lin Wang1, Jun Ma1, Wei Jiang1, Yongxing Zhang1, Yu Shi1*, Qun Wang1*

1 Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, 2 Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China

* wang.qun@zs-hospital.sh.cn (QW); shi.yu@zs-hospital.sh.cn (YS)

Abstract

Muscle type of pyruvate kinase (PKM) is one of the key mediators of the Warburg effect and tumor metabolism. Due to alternative splicing, there are at least 12 known isoforms of the PKM gene, of which PKM1 and PKM2 are two major isoforms with only a 23 amino acid sequenced difference but quite different characteristics and functions. It was previously thought the isoform switch from PKM1 to PKM2 resulted in high PKM2 expression in tumors, providing a great advantage to tumor cells. However, this traditional view was challenged by two recent studies; one study claimed that this isoform switch does not occur during the Warburg effect; the other study asserted that the isoform switch is tissue-specific. Here, we re-analyzed the RNA sequencing data of 25 types of human tumors from The Cancer Genome Atlas Data Portal, and confirmed that PKM2 was the major isoform in the tumors and was highly elevated in addition to the entire PKM gene. We further demonstrated that the expression level of PKM1 significantly declined even though there was substantially increased expression of the entire PKM gene. The proportion of PKM1 in total transcript variants also significantly declined in tumors but the proportion of PKM2 did not change accordingly. Therefore, we conclude that the isoform switch of PKM1 does indeed occur, but it switches to other isoforms rather than PKM2. Considering the change in the expression levels of PKM1, PKM2 and the entire PKM gene, we propose that the upregulation of PKM2 is primarily due to elevated transcriptional levels of the entire PKM gene, instead of the isoform switch.

Introduction

Numerous metabolic changes during tumorigenesis have received increased attention in recent years. The best known and probably most central change is the unusually high rate of glycolysis and lactate production, which was originally described by Otto Warburg in the 1920s, and was subsequently termed the Warburg effect. Although the mechanisms underlying the Warburg effect are not completely understood, it is widely thought that muscle type of pyruvate kinase (PKM) plays a key role.
The PKM gene produces two major alternatively spliced isoforms, PKM1, which is constitutively active, and PKM2, which can switch between an active tetrameric and more common inactive dimer form. PKM2 is highly upregulated in cancer cells, and the dynamic tuning of its activity causes the transition from aerobic respiration to glycolysis. This transition is customarily believed to result in the accumulation of phosphoenolpyruvate and other glycolytic intermediates, and consequently, the redirection of glucose for macromolecule isosynthesis rather than ATP production, which provides a great advantage for the growth and division of cancer cells. Currently, there are 10 other isoforms of the PKM gene recorded in the University of California Santa Cruz (UCSC) Genome Bioinformatics database (http://genome.ucsc.edu), but their characteristics, functions, and expression have received little attention and remain unclear.

For decades, it was widely believed that PKM1 was specific for non-proliferating tissues and PKM2 for proliferating tissues, and that the isoform switch from PKM1 to PKM2 was the main reason for increased PKM2 expression in cancers [1–3]. However, in 2011, Bluemlein et al. [4] demonstrated that PKM2 was not specific for tumors. In addition, she found no evidence of a PKM1 to PKM2 isoform shift during tumorigenesis [4]. In 2013 Desai et al. [5] claimed that the isoform switch from PKM1 to PKM2 only occurred in glioblastomas, and not in other tumor types based on The Cancer Genome Atlas (TCGA) data analysis. With the exception of the two aforementioned studies, there is no additional evidence on whether the PKM1 to PKM2 isoform switch occurs. Here, we reanalyzed data generated by the TCGA Research Table 1. The number of normal samples and tumor samples in each tissue type.

| Tissue Type                                         | Normal | Tumor |
|----------------------------------------------------|--------|-------|
| Acute Myeloid Leukemia (LAML)                      | 0      | 173   |
| Adrenocortical carcinoma (ACC)                     | 0      | 79    |
| Bladder Urothelial Carcinoma (BLCA)                | 19     | 241   |
| Brain Lower Grade Glioma (LGG)                     | 0      | 469   |
| Breast invasive carcinoma (BRCA)                   | 110    | 1034  |
| Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) | 3      | 196   |
| Colon adenocarcinoma (COAD)                        | 41     | 262   |
| Glioblastoma multiforme (GBM)                      | 0      | 169   |
| Head and Neck squamous cell carcinoma (HNSC)       | 43     | 498   |
| Kidney Chromophobe (KICH)                          | 25     | 66    |
| Kidney renal clear cell carcinoma (KIRC)           | 72     | 519   |
| Kidney renal papillary cell carcinoma (KIRP)       | 30     | 198   |
| Liver hepatocellular carcinoma (LIHC)              | 50     | 191   |
| Lung adenocarcinoma (LUAD)                         | 58     | 490   |
| Lung squamous cell carcinoma (LUSC)                | 50     | 490   |
| Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) | 0      | 28    |
| Ovarian serous cystadenocarcinoma (OV)             | 0      | 266   |
| Pancreatic adenocarcinoma (PAAD)                   | 3      | 85    |
| Prostate adenocarcinoma (PRAD)                     | 50     | 333   |
| Rectum adenocarcinoma (READ)                       | 9      | 164   |
| Sarcoma (SARC)                                     | 2      | 105   |
| Skin Cutaneous Melanoma (SKCM)                     | 1      | 373   |
| Thyroid carcinoma (THCA)                           | 29     | 275   |
| Uterine Carcinosarcoma (UCS)                       | 0      | 57    |
| Uterine Corpus Endometrial Carcinoma (UCES)        | 23     | 529   |
| Total                                              | 618    | 7290  |

doi:10.1371/journal.pone.0118663.t001

Competing Interests: The authors have declared that no competing interests exist.
Network, and concluded that a PKM1 isoform switch did indeed occur, but it switched to other isoforms rather than PKM2. Instead, the upregulation of PKM2 in human tumors was primarily due to elevated transcriptional levels of the entire gene.

Material and Methods

Data acquisition and processing

Level 3 RNA sequencing (RNA-Seq) V2 data (contains data on gene, isoform, exon, and junction levels), which was released by TCGA before April 15, 2014, were downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp), and included 618 human normal samples and 7,290 tumor samples from 25 tissue types (Table 1). Fourteen transcript variants of PKM were identified from TCGA data, including uc002atr.1, uc002ats.1, uc002att.1, uc002atu.1, uc002atv.1, uc002atw.1, uc002aty.1, uc002atz.1, uc010bit.1, uc010bui.1, uc010uki.1, uc010ukj.1, and uc010ukk.1. The sequences of these transcript variants and their protein products were obtained from UCSC Genome Bioinformatics. These sequences were compared to the PKM gene sequence recorded in the NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene) using BLAST to determine the transcriptional patterns of these 14 transcript variants. Finally, we assigned uc002atw.1 and uc002atx.1 to PKM1, and uc002aty.1 to PKM2. RNA-Seq by expectation maximization (RSEM) values were used to represent the expression levels of these transcript variants. Data were presented as mean ± standard error of mean (SEM).

Statistical analysis

Data were analyzed using IBM SPSS for Windows, Version 20 (Armonk, NY, USA). Student’s t-test was used to evaluate the expression differences and Mann-Whitney U test was used to evaluate the percentage differences of PKM isoforms between normal and tumor samples.

Results

Transcript variants and isoforms of PKM

To study the expression profiles of PKM and its isoforms in human tumors, we analyzed TCGA Level 3 expression data from samples that were profiled using RNA-Seq technology, and identified 14 transcript variants of PKM. PKM1, PKM2, and 10 other known isoforms are translated from these transcript variants. The transcriptional patterns of these transcript variants are shown in Fig. 1. Of these transcript variants, uc002atw.1 and uc002atx.1 are translated to PKM1, and uc002aty.1 is translated to PKM2. PKM1 and PKM2 only differ by 23 amino acid residues within a 56-residue alternatively spliced exon.

In Desai et al. [5], the authors confused the transcript variants of PKM, and incorrectly assigned uc002att.1, uc002atv.1, uc002atx.1, uc002aty.1, uc010bit.1, uc010bui.1, uc010uki.1, uc010ukj.1, and uc010ukk.1 to PKM1, and uc002atr.1, uc002ats.1, uc002atu.1, uc002atz.1, uc010bui.1, uc010uki.1, uc002atz.1 to PKM2. This mistake resulted in their inaccurate results and conclusions.

The RSEM value of each transcript variant was calculated, and the results are summarized in S1 and S2 Tables. The number of normal and tumor samples, and the expression levels of each transcript variant of PKM in each tissue type are also shown.

PKM expression is highly elevated in human tumors

As shown in Fig. 2 and S3 Table, PKM is a highly expressed gene with a RSEM value of more than 10,000 in both normal and tumor tissues of each organ, except the liver. In addition, PKM expression is elevated in most human tumors. The results of our statistical analyses showed that in 18 kinds of tumors with normal sample controls available, PKM expression significantly
increased in 14 tumor types and significantly decreased in only one tumor type, whereas in the other three tumor types, the difference in expression between the tumor and control samples was not statistically significant.

PKM2 expression increases in human tumors, but its proportion does not change

As shown in Fig. 3 and S3 Table, PKM2 expression significantly increased in 13 tumor types, and did not significantly decrease in any of the tumors, similar to PKM. PKM2 was the major isoform identified, and accounted for 51.9–87.2% of all isoforms in both normal and tumor samples in the 25 tissue types. Although PKM2 expression significantly increased in most tumor types, the percentage of PKM2 in the total transcript variants did not significantly change. The results of the statistical analyses showed that the proportion of PKM2 significantly increased in three tumor types, and decreased in six cancer types, whereas in the other nine cancer types the difference in expression was not statistically significant.
Expression and proportion of PKM1 both decrease in human tumors

As shown in Fig. 4 and S3 Table, PKM1 only accounted for a small proportion of total transcripts, ranging from 0.1% to 17.8%, which was much lower than the amount of PKM2, even in normal tissues. PKM1 expression significantly decreased in eight tumor types, and did not significantly increase in any tumor type. Taking into account the increased expression of the entire PKM gene, the percentage of PKM1 decreased more significantly in tumors compared with normal control samples. The percentage of PKM1 in total transcript variants significantly decreased in 11 tumor types and only significantly increase in one tumor type.

Fig 3. Expression and proportion of PKM2 in human tumors. (A) Expression of PKM2; (B) Proportion of PKM2. Expression of PKM2 increased, but the proportion did not change in human tumors.

doi:10.1371/journal.pone.0118663.g003
Increase in PKM2 expression is much greater than the decrease in PKM1 in human tumors

As shown in Fig. 5, PKM1 expression only changed by several hundred RSEM, whereas PKM2 expression increased by RSEM values of tens of thousands in most tumor types. The change in PKM2 expression was 4.5- to 200-fold greater than that of PKM1 in all human tumors, except prostate adenocarcinoma. Thus, we postulated that the upregulation of PKM2 in human tumors compared with normal control samples is not due to changes in PKM1 levels.

Discussion

In this study, we examined the mRNA profile of PKM in many types of human tumors based on TCGA data. We discovered that the expression level of PKM1 significantly declined even...
though there was substantially increased expression of the entire PKM gene in most human tumors. Both the expression and proportion of PKM1 declined, indicating that the PKM1 isoform switch did indeed occur. However, the proportion of PKM2 did not increase as PKM1 levels decreased. We found that the isoforms whose proportions were most increased were uc002atr.1 and uc002ats.1 (S1 and S2 Tables), rather than PKM2. Therefore, we postulated that PKM1 isoform switch did occur, but not to PKM2 in human tumors. Instead, it appeared that the upregulation of PKM2 was primarily due to the elevated transcriptional level of the entire PKM gene, because the change in PKM2 was consistent with PKM, and was far greater than the change in PKM1 expression levels.

Previous studies reported that PKM1 dominated in normal tissues and its dominance was replaced by PKM2 in cancer development [1–3]. In fact, these results were mostly derived by Western blot or immunohistochemistry, both of which were based on the reaction of antigen and antibody in protein level, unable to accurately quantify the expression of PK isoforms or distinguish their dominances. In a new research, Wilhelm et al. [6] discovered that the mRNA/protein ratio was remarkably conserved for each protein, and the actual amount of protein was primarily controlled by mRNA levels; therefore, the protein abundance of the PKM isoforms were supposed to be consistent with their mRNA profiles analyzed in our investigation. Now it is no doubted in the tremendous elevation of PKM2 in tumors, and Christofk et al. [2] have demonstrated that the elevated PK2 expression was necessary for aerobic glycolysis and provided a selective growth advantage for tumor cells. In Bluemlein et al. [4], the authors demonstrated for the first time that the PKM2 protein was the dominant isoform of PKM by quantitative mass spectrometry in both normal and tumor tissues and this finding was validated by our analysis of the TCGA RNA-Seq data. In our research, we confirmed that PKM1 significantly declined in many types of tumors, which was consistent with previous studies but not the results of Bluemlein et al. [2–4]. Due to the small sample number and low levels of PKM1 expression, the study by Bluemlein et al. [4] might not have been sensitive enough to detect the dip in PKM1 expression. Considering the change of PKM, PKM1 and PKM2, We believed the elevation of PKM2 was primarily due to the elevation of the entire PKM gene, instead of the switch of PKM1.

Fig 5. Change in expression of PKM1 and PKM2 in human tumors compared with normal tissues. There was little change in PKM1 expression, whereas there was a significant increase in PKM2 in human tumors.

doi:10.1371/journal.pone.0118663.g005
In the study by Desai et al. [5], the authors confused the isoforms of PKM, so what they thought was "PKM1" was actually a set of PKM isoforms, and similarly for "PKM2". This may lead to that their conclusion differs from ours. With the exception of PKM1 and PKM2, the characteristics and functions of the other isoforms remain unclear.

We noticed that prostate adenocarcinoma was the only cancer type in which PKM significantly decreased compared with the normal controls, perhaps due to the slow growing nature of this cancer [7]. In addition, there was lower expression of PKM in liver tissues and hepatocellular carcinomas, probably because of the high proportion of liver and red blood cell type of pyruvate kinase (PKLR, 80.6% in normal liver samples, 46.4% in hepatocellular carcinomas, and less than 1% in most other samples) (S1 Fig.).

We observed that many other glycolytic enzymes, such as hexokinase 2 (HK2), phosphoglycerate kinase 1 (PGK1), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and lactate dehydrogenase A (LDHA) were increased in most tumors in the TCGA data portal (S2 Fig.), consistent with numerous studies [8–20]. In addition, there was a strong positive correlation with the expression of these glycolytic enzymes. Therefore, these glycolytic enzymes may be regulated by tumorigenic factors or may regulate tumorigenesis in parallel. For one example, many glycolytic enzymes are highly correlated with tumor prognosis [5,12–28]; for another example, hypoxia inducible factor-1 (HIF-1) is one of the key regulators of many glycolytic enzymes and of the Warburg effect [13,21,29–35].

For the past few years, PKM2 was found to not only act as a key enzyme of glycolysis in cytoplasm, but also can be translocated into the nucleus of tumor cells via many different mechanisms [36,37]. The nuclear PKM2 interacts with a lot of molecules important in regulating gene transcription and promoting cell proliferation, such as nuclear histone 1, signal transducers and activators of transcription 3 (STAT3), phosphorylates prothymosin a, b-catenin, HIF-1, and octamer-binding transcription factor 4 (Oct-4) [38–45]. Some of these interactions were believed to be caused by the protein kinase activity of PKM2 [38,42]. In addition, GAPDH and aldolase A undergo nuclear translocation in some cases, and promote cell proliferation or apoptosis, too [46,47].

In recent years, RNA-Seq has emerged as a popular and powerful tool for high throughput whole genome analysis, including transcript quantification, differential expression testing, reference-based gene annotation, and de novo transcript assembly. Using this technique, transcript levels are usually normalized by RSEM or reads per kilobases per million mapped reads (RPKM), which ideally facilitate the transparent comparison between multiple genes and samples [48,49]. As such, RNA-Seq will play an increasingly important role in future research studies.

Supporting Information

S1 Fig. Expression of PKLR and proportion of PKLR in PKM and PKLR in human tumors. (TIF)

S2 Fig. Expression of HK2, GAPDH, PGK1 and LDHA in human tumors. (TIF)

S1 Table. Expression and proportion of 14 PKM transcript variants in normal tissue samples. Transcript variants uc002atw.1 and uc002atx.1 are translated to M1; uc002aty.1 is translated to M2. Data are presented by mean and SEM. (DOC)

S2 Table. Expression and proportion of 14 PKM transcript variants in tumor tissue samples. (DOC)
S3 Table. Expression and proportion of PKM1, PKM2, and PKM.

Acknowledgments
The results published here are based upon data generated by the TCGA Research Network (http://cancergenome.nih.gov/).

Author Contributions
Conceived and designed the experiments: QW YS CZ. Performed the experiments: CZ LY LW JM. Analyzed the data: CZ LY LW. Contributed reagents/materials/analysis tools: JM WJ YZ. Wrote the paper: CZ LY WJ YZ YS.

References
1. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int J Biochem Cell Biol. 2011; 43: 969–980. doi:10.1016/j.biocel.2010.02.005 PMID: 20156581
2. Christofk HR, Vander HM, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452: 230–233. doi:10.1038/nature06734 PMID: 18337823
3. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005; 15: 300–308. PMID:15908230
4. Bluemlein K, Gruning NM, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. Oncotarget. 2011; 2: 399–400. PMID: 21789790
5. Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. Oncotarget. 2013.
6. Wilhelm M, Schlegl J, Hahne H, Moghadass GA, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014; 509: 582–587. doi:10.1038/nature13319 PMID: 24870543
7. Saman DM, Lemieux AM, Nawal LM, Lipsky MS. A review of the current epidemiology and treatment options for prostate cancer. Dis Mon. 2014; 60: 150–154. doi:10.1016/j.disamonth.2014.02.003 PMID: 24726082
8. Chen J, Sun MX, Hua YQ, Cai ZD. Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis. J Cancer Res Clin Oncol. 2014; 140: 1205–1210. doi:10.1007/s00432-014-1644-0 PMID: 24682990
9. Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013; 42: 44–54. doi:10.3892/ijo.2012.1687 PMID: 23135628
10. Tang Z, Yuan S, Hu Y, Zhang H, Wu W, Zeng Z, et al. Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester. J Bioenerg Biomembr. 2012; 44: 117–125. doi:10.1007/s10863-012-9420-9 PMID: 22350014
11. Zhan C, Zhang Y, Ma J, Wang L, Jiang W, Shi Y, et al. Identification of reference genes for qRT-PCR in human lung squamous-cell carcinoma by RNA-Seq. Acta Biochim Biophys Sin (Shanghai). 2014; 46: 330–337. doi:10.1093/abbs/gnt153 PMID: 24457517
12. Zhan C, Shi Y, Lu C, Wang Q. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer. Dis Esophagus. 2013; 26: 746–753. doi:10.1111/dote.12023 PMID: 23317289
13. Yao Y, Wang H, Li B. LDH5 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis. Tumour Biol. 2014.
14. Song Y, Luo Q, Long H, Hu Z, Que T, Zhang X, et al. Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. Mol Cancer. 2014; 13: 65. doi: 10.1186/1476-4598-13-65 PMID: 24650096
15. Yuan C, Li Z, Wang Y, Qi B, Zhang W, Ye J, et al. Overexpression of metabolic markers PKM2 and LDH5 correlates with aggressive clinicopathological features and adverse patients’ prognosis in tongue cancer. Histopathology. 2014.
16. Puzone R, Savarino G, Salvi S, Dal Bello MG, Barletta G, Genova C, et al. Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patients. Mol Cancer. 2013; 12: 97. doi: 10.1186/1476-4598-12-97 PMID: 23988223

17. Zhang X, He C, He C, Chen B, Liu Y, Kong M, et al. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013; 209: 510–515. doi: 10.1016/j.prp.2013.06.005 PMID: 23880164

18. Teng Y, Ai Z, Wang Y, Wang J, Luo L. Proteomic identification of PKM2 and HSPA5 as potential bio-markers for predicting high-risk endometrial carcinoma. J Obstet Gynaecol Res. 2013; 39: 317–325. doi: 10.1111/j.1447-0756.2012.01970.x PMID: 22889453

19. Wang D, Mothart DR, Lowy DR, Qian X. The expression of glyceraldehyde-3-phosphate dehydrogenase associated cell cycle (GACC) genes correlates with cancer stage and poor survival in patients with solid tumors. PLoS One. 2013; 8: e61262. doi: 10.1371/journal.pone.0061262 PMID: 23620736

20. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH, et al. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. World J Gastroenterol. 2012; 18: 4037–4043. doi: 10.3748/wjg.v18.i30.4037 PMID: 22912555

21. Peremalm M, De Petrissi L, Branca RM, Forshed J, Kanter L, Soria JC, et al. Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism. J Proteome Res. 2013; 12: 3934–3943. doi: 10.1021/pr4002096 PMID: 23902561

22. Sato-Tadano A, Suzuki T, Amari M, Takagi K, Miki Y, Tamaki K, et al. Hexokinase II in breast carcinoma: a potent prognostic factor associated with hypoxia-inducible factor-1alpha and Ki-67. Cancer Sci. 2013; 104: 1380–1388. doi: 10.1111/cas.12238 PMID: 23869589

23. Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep. 2008; 19: 1045–1053. PMID: 18357395

24. Li J, Yang Z, Zou Q, Yuan Y, Li J, Liang L, et al. PKM2 and ACVR1C are prognostic markers for poor prognosis of gallbladder cancer. Clin Transl Oncol; 2014; 16: 200–207. doi: 10.1007/s12094-013-1063-8 PMID: 23793810

25. Girgis H, Masui O, White NM, Scorilas A, Rotondo F, Seiwright A, et al. Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. Mol Cancer. 2013; 14: 101. doi: 10.1186/1476-4598-13-101 PMID: 24885701

26. Falkenius J, Lundeberg J, Johansson H, Tuominen R, Frostvik-Stolt M, Hansson J, et al. High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma. Melanoma Res. 2013; 23: 452–460. doi: 10.1097/CMR.0b013e3182a8e8b3 PMID: 24218789

27. Dennison JB, Molina JR, Mitra S, Gonzalez-Angulo AM, Balko JM, Kuba MG, et al. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2013; 19: 3703–3713. doi: 10.1158/1078-0432.CCR-13-0623 PMID: 23697991

28. Chen J, Zhang S, Li Y, Tang Z, Kong W. Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma. Tumour Biol. 2014; 35: 3743–3753. doi: 10.1007/s13277-013-1496-2 PMID: 24340631

29. He G, Jiang Y, Zhang B, Wu G. The effect of HIF-1alpha on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pac J Clin Nutr. 2014; 23: 174–180. doi: 10.6133/apjcn.2014.23.1.14 PMID: 24561986

30. Lu H, Li X, Luo Z, Liu J, Fan Z. Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol Cancer Ther. 2013; 12: 2187–2199. doi: 10.1158/1535-7163.MCT-12-1245 PMID: 23920275

31. Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc. 2007: 35–53. PMID: 18811052

32. Kress S, Stein A, Maurer P, Weber B, Reichert J, Buchmann A, et al. Expression of hypoxia-inducible genes in tumor cells. J Cancer Res Clin Oncol. 1998; 124: 315–320. PMID: 9692838

33. Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1alpha and lincRNA-p21 modulates the Warburg effect. Mol Cell. 2014; 53: 88–100. doi: 10.1016/j.molcel.2013.11.004 PMID: 24316222

34. Guo Y, Meng X, Ma J, Zheng Y, Wang Q, Wang Y, et al. Human papillomavirus 16 E6 contributes HIF-1alpha induced Warburg effect by attenuating the VHL-HIF-1alpha interaction. Int J Mol Sci. 2014; 15: 7974–7986. doi: 10.3390/ijms15057974 PMID: 24810689

35. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr. 2007; 39: 231–234. PMID: 17551816

36. Hoshino A, Hirst JA, Fuji H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. J Biol Chem. 2007; 282: 17706–17711. PMID: 17446165
37. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwierschke W. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res. 2009; 315: 2765–2774. doi: 10.1016/j.yexcr.2009.06.024 PMID: 19563799

38. Ignacak J, Stachurska MB. The dual activity of pyruvate kinase type M2 from chromatin extracts of neoplastic cells. Comp Biochem Physiol B Biochem Mol Biol. 2003; 134: 425–433. PMID: 12628374

39. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011; 480: 118–122. doi: 10.1038/nature10598 PMID: 22056988

40. Luo W, Hu H, Chang R, Zhong J, Knabel M, O’Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell. 2011; 145: 732–744. doi: 10.1016/j.cell.2011.03.054 PMID: 21620138

41. Diaz-Jullien C, Moreira D, Sarandeses CS, Covelo G, Barbeito P, Freire M. The M2-type isoenzyme of pyruvate kinase phosphorylates prothymosin alpha in proliferating lymphocytes. Biochim Biophys Acta. 2011; 1814: 355–365. doi: 10.1016/j.bbapap.2010.10.004 PMID: 20977946

42. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell. 2012; 45: 598–609. doi: 10.1016/j.molcel.2012.01.001 PMID: 22306293

43. Wang HJ, Hsieh YJ, Cheng WC, Lin CP, Lin YS, Yang SF, et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism. Proc Natl Acad Sci U S A. 2014; 111: 279–284. doi: 10.1073/pnas.1311249111 PMID: 24344305

44. Stetak A, Veress R, Ovadi J, Csermely P, Keri G, Ullrich A. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res. 2007; 67: 1602–1608. PMID: 17308100

45. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012; 14: 1295–1304. doi: 10.1038/ncb2629 PMID: 23178880

46. Dando I, Fiorini C, Pozza ED, Padroni C, Costanzo C, Palmieri M, et al. UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2013; 1833: 672–679. doi: 10.1016/j.bbapap.2012.10.028 PMID: 23124112

47. Mamczur P, Gamian A, Kolodziej J, Dziegieł P, Rakus D. Nuclear localization of aldolase A correlates with cell proliferation. Biochim Biophys Acta. 2013; 1833: 2812–2822. doi: 10.1016/j.bbapap.2013.07.013 PMID: 23886627

48. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12: 323. doi: 10.1186/1471-2105-12-323 PMID: 21816040

49. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008; 5: 621–628. doi: 10.1038/nmeth.1226 PMID: 18516045